HLA-B27: what's new?

HLA-B27: what's new?

The HLA-B27 molecule is one of the most fascinating in medicine. Its contribution to the aetiopathogenesis of SpA and other diseases, and its protective action in certain infections, continue to challenge our understanding of its immunobiology and physiological roles. Animal studies have helped to cast light on ways in which HLA-B27 exerts its effects. Subtle variations in structure and behavio...

Arthritis and HLA-B27 in Papua New Guinea.

Acute Anterior Uveitis and HLA-B27: What’s New?

■ Acute anterior uveitis (AAU) accounts for 90% of all uveitis cases seen by the general ophthalmologist. ■ About half of all AAU cases are HLA-B27associated. ■ HLA-B27+ AAU represents a distinct clinical entity with important ocular and extraocular consequences. ■ The typical ocular phenotype of HLA-B27+ AAU is that of acute onset, unilateral inflammation of the iris and ciliary body, with a t...

HLA-B27 and Ankylosing Spondylitis

Ankylosing spondylitis (AS) is a chronic inflammatory disease with potential disabling outcomes. Clinically, patients presented with inflammatory lower back pain, enthesis and alternated buttock pain (van der Linden & van der Heijde, 1998). Bernard Corner (16661698) was the first physician who published the clinical features of AS in his medical thesis (Baker & Weisman, 2006). In the late 19th ...

Complement activation and HLA-B27.

The efficiency of complement activation was studied in sera from HLA-B27 positive and negative subjects (27 with previous yersinia arthritis and 35 controls). Activation of complement with zymosan induced higher mean levels of the anaphylatoxin C3a in HLA-B27 positive sera (mean (SD) 7.40 (1.66) mg/l) than in HLA-B27 negative sera (6.41 (1.79) mg/l). Similarly, higher levels of C3d,g, another C...